# GHK-Cu — questions answered from the published research literature

> Questions and answers about GHK-Cu drawn from the peer-reviewed research literature: mechanism, dose ranges studied, half-life, human trial data, regulatory status, and what the published record does and does not show.

What the literature answers, what it does not, and where the regulatory boundaries actually sit.

## What is GHK-Cu?

GHK-Cu is a tripeptide-copper complex. The peptide is three amino acids long — glycine, histidine, lysine — bound to a single divalent copper ion. The free peptide weighs 340.38 Da; the copper complex is 403.93 Da. The complex was first isolated from human plasma in 1973 by Loren Pickart. The same Gly-His-Lys sequence is present in the alpha-2(I) chain of type I collagen and is thought to be released by proteases during tissue injury, which gives the molecule a plausible endogenous role as a damage-released signal [1]. Cosmetic ingredient nomenclature lists it as Copper Tripeptide-1.

## How does GHK-Cu work at a cellular level?

Two functions are central. First, the complex delivers redox-silenced Cu(II) to copper-dependent enzymes — lysyl oxidase, SOD1, cytochrome c oxidase — in a controlled way that avoids the toxicity of free copper [1]. Second, GHK acts as a broad gene-expression modulator. Connectivity Map analyses estimate it influences expression of approximately 31% of human genes [2]. The transcriptional pattern is consistent: upregulation of tissue-repair, antioxidant, and DNA-repair programs and downregulation of inflammatory and pro-fibrotic signaling. Specific pathways activated include Nrf2 antioxidant signaling and Wnt/β-catenin (hair follicle dermal papilla); pathways suppressed include NF-κB and TGF-β1/Smad-mediated epithelial-mesenchymal transition in fibrosis [7].

## What does the research say about GHK-Cu and collagen?

The collagen story is the deepest part of the literature. Maquart and colleagues established in 1988 that GHK-Cu induces collagen synthesis in human dermal fibroblast culture at picomolar concentrations (10⁻¹² M), with full effect at nanomolar (10⁻⁹ M) [3]. A 1998 head-to-head trial in human thigh skin reported topical GHK-Cu outperformed both vitamin C and retinoic acid on measured collagen increase — 70% of subjects responded to GHK-Cu versus 50% to vitamin C and 40% to retinoic acid [5]. A 2024 IRB-approved trial in 21 women reported a 28% mean increase in dermal collagen by histology after 3 months of daily topical gel, with the top quartile of responders reaching 51% [9]. A 2016 nano-lipid carrier formulation produced a 31.6% reduction in wrinkle volume over 8 weeks [8].

## What does the research say about GHK-Cu and hair?

GHK-Cu has been studied in hair follicle dermal papilla cells as an activator of Wnt/β-catenin signaling [1]. Commercial hair products incorporating copper peptides have been marketed for decades. The published controlled-trial evidence for hair regrowth in humans is thinner than the dermal-collagen evidence — much of what circulates online conflates mechanistic plausibility with clinical proof. Vendor marketing claims that compare GHK-Cu directly to topical minoxidil should be read cautiously; head-to-head efficacy data of that kind are not well represented in peer-reviewed literature [1].

## What are common research doses of GHK-Cu in published studies?

Doses depend on route and endpoint. In vitro fibroblast collagen induction starts at 10⁻¹² M and saturates at 10⁻⁹ M [3]. Rodent intraperitoneal behavioral studies have used as little as 0.5 μg/kg [15]; anti-fibrosis work in mice used 0.2 to 20 μg/g/day [7]; the 5xFAD Alzheimer's mouse model used 15 mg/kg intranasally three times weekly [13]; the sleep-deprivation aged-mouse cognition study used 15 mg/kg/day intraperitoneally [16]. Topical cosmetic and wound-healing studies have used 0.05% to 2% w/w formulations [1][6]. Every figure here is a research-context dose, not a human-prescribing dose. Detailed records are on the [doses studied](/dosage) page.

## Is GHK-Cu safe in research models?

The acute toxicology in mice is reassuring — the reported LD50 is roughly 8 mg per 25 g mouse, equivalent to approximately 320 mg/kg [1]. That figure substantially exceeds the doses used in any published efficacy study. Chronic human safety data, particularly for injectable use, is essentially absent at scale; the published topical clinical record (12-week facial creams, diabetic foot ulcer gels) is the most established safety frame [4][6]. Copper itself is toxic at high doses, so total copper exposure becomes relevant in chronic high-dose research scenarios. Commercial product quality varies widely, and a 2016 analysis flagged poorly chelated formulations as a possible source of skin irritation or oxidative stress [1].

## What is the half-life of GHK-Cu?

Plasma half-life in published rodent pharmacokinetics is on the order of minutes [1]. The biological effect substantially outlasts the plasma levels, which is consistent with a transient signal that triggers durable transcriptional changes rather than a sustained receptor-occupancy mechanism. This short plasma half-life is also why much of the recent translational research has moved to local routes — intranasal delivery for CNS endpoints [13], implanted collagen depots for wound and nerve repair [17][18], and topical formulations for skin [8].

## Does GHK-Cu have any human clinical trial data?

Yes, but the trials are small and topical. A 12-week study in 71 women using a daily topical facial cream reported increased skin density and thickness [4]. A 1998 head-to-head trial reported topical GHK-Cu outperformed vitamin C and retinoic acid on collagen induction in 70% of subjects [5]. A 1994 randomized placebo-controlled trial of 2% topical gel in diabetic foot ulcers (the Iamin Gel product, since discontinued commercially) increased wound closure rates versus placebo [6]. A 2024 IRB-approved 21-subject trial reported a 28% mean dermal collagen increase by histology [9]. No large injectable GHK-Cu trials in humans have been published. The most active current translation pipeline is intranasal GHK in cognitive-decline preclinical models [13].

## How is GHK-Cu different from regular copper supplementation?

Free copper and GHK-bound copper behave differently in the same assay. A 1990 study reported GHK-Cu reduced iron release from ferritin by 87% and completely blocked Cu(II)-dependent oxidation of low-density lipoproteins — outperforming superoxide dismutase, which gave only ~20% protection [20]. The implication is that the coordination geometry of the complex is what makes the copper bioavailable in a redox-buffered, controlled-delivery way; uncomplexed Cu(II) is a Fenton-chemistry reactant that can drive oxidative damage, while GHK-coordinated Cu(II) is redox-silenced and donated to enzymes on demand [1]. The 2024 *Metallomics* CNS work extends this principle: GHK at concentrations from 0 to 1000 μM prevented Cu/Zn-induced cell death in primary CNS cells and resolubilized aggregated proteins — a behavior uncomplexed copper does not show [14].

## What recent (2024–2025) research exists on GHK-Cu?

Four recent papers anchor the current literature. A 2024 *Metallomics* study established that GHK prevents copper- and zinc-induced protein aggregation and cell death in primary CNS cells [14]. A 2024 *Aging Pathobiology and Therapeutics* paper reported GHK reverses age-related fibrosis by modulating myofibroblast function — reducing senescence markers p21 and p53 and lowering TGF-β1 secretion in aged primary mouse lung fibroblasts [22]. A 2024 *PRIME Journal* editorial review summarized IRB-approved trial data reporting a 28% mean dermal collagen increase after 3 months of topical GHK-Cu [9]. A 2026 systematic review in *Dermatological Reviews* concluded that GHK-Cu and related copper peptides have the strongest mechanistic and clinical evidence base among signal peptides currently in aesthetic dermatology use [26]. The 2023 Tucker intranasal Alzheimer's mouse work [13] remains the most cited recent CNS finding.

## Is GHK-Cu the same as the cosmetic ingredient Copper Tripeptide-1?

Yes. Copper Tripeptide-1 is the INCI (International Nomenclature of Cosmetic Ingredients) classification used to identify GHK-Cu in cosmetic formulations. The INCI listing covers topical use only and is a regulatory ingredient designation, not a medical-drug approval [1]. The Copper Tripeptide-1 ingredient name has appeared in dermatologic and cosmetic products since the 1990s.

## What is the regulatory status of GHK-Cu?

GHK-Cu is not approved by the FDA, EMA, or any major drug regulator for any human therapeutic indication [1]. The cosmetic ingredient classification (Copper Tripeptide-1) covers topical cosmetic use only. The 1990s Iamin Gel product (2% topical GHK-Cu for diabetic foot ulcers) reached Phase III development and was subsequently discontinued; no successor injectable product has been advanced to large-scale human trials [1]. The compound's regulatory status as a research peptide outside cosmetic use means all non-topical use remains in research and laboratory contexts.

## Is GHK-Cu on the WADA prohibited list?

GHK-Cu is not explicitly enumerated by name on the 2025 WADA Prohibited List, but the absence of a name listing does not equal a clean status. Depending on context, GHK-Cu may fall under S0 (Non-Approved Substances) when used in injectable form, and could potentially implicate S2 (Peptide Hormones, Growth Factors, and Related Substances) categories depending on how the regulatory body interprets gene-expression-modulating peptides. Athletes subject to anti-doping rules should consult WADA and their national federation directly — the analysis on this site is not a competition-eligibility opinion [1].

## What are the limits of the current evidence?

Three limits are honest to name. First, most positive efficacy data comes from in vitro and rodent models; large-scale human RCTs remain limited even after fifty years of research history. Second, the bioavailability of topical GHK-Cu through intact stratum corneum is contested, and delivery vehicle (liposomes, nano-lipid carriers, microneedling) materially affects penetration. Third, vendor marketing claims for systemic anti-aging or hair-regrowth effects often extrapolate well beyond what controlled human trials have shown — the in vitro and rodent literature is rich, but the human-scale generalization is not as well established as marketing copy implies [1].

---

An independent working file on the published GHK-Cu literature — not a clinic, not a vendor, not a prescription.